← Orthofix Medical Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $409.8m |
$433.8m
+5.87%
|
$453.0m
+4.43%
|
$460.0m
+1.53%
|
$406.6m
-11.61%
|
$464.5m
+14.25%
|
$460.7m
-0.81%
|
$746.6m
+62.06%
|
$799.5m
+7.08%
|
$822.3m
+2.85%
|
$833.2m
+1.32%
|
|
| Cost of Revenue | $87.9m |
$93.0m
+5.90%
|
$96.6m
+3.86%
|
$100.6m
+4.12%
|
$101.9m
+1.27%
|
$114.9m
+12.78%
|
$123.5m
+7.51%
|
$260.4m
+110.75%
|
$253.6m
-2.60%
|
$256.3m
+1.06%
|
$239.1m
-6.72%
|
|
| Gross Profit | $321.9m |
$340.8m
+5.86%
|
$356.4m
+4.59%
|
$359.3m
+0.82%
|
$304.7m
-15.22%
|
$349.6m
+14.73%
|
$337.2m
-3.55%
|
$486.3m
+44.22%
|
$545.9m
+12.26%
|
$566.0m
+3.69%
|
$594.1m
+4.96%
|
|
| Interest Income (Expense), Net | $763k |
($416k)
-154.52%
|
($828k)
-99.04%
|
($122k)
+85.27%
|
($2.5m)
-1935.25%
|
($1.8m)
+26.02%
|
($1.3m)
+29.89%
|
($8.6m)
-570.11%
|
($29.6m)
-243.31%
|
($17.5m)
+40.98%
|
— | |
| Research and Development Expense | $28.8m | $29.7m | $33.2m | $34.6m | $39.1m | $49.6m | $49.1m | $80.2m | $73.6m | $65.8m | $61.4m | |
| Selling, General and Administrative Expense | — | — | — | — | — | — | — | — | $532.5m | $554.3m | $557.8m | |
| Amortization of Intangible Assets | $1.8m | $1.8m | $2.7m | $7.0m | $11.2m | $9.4m | $9.4m | $18.9m | $19.0m | $30.0m | — | |
| Restructuring Costs | $3.0m | — | — | — | — | — | — | — | — | — | — | |
| Operating Expenses | $300.9m | $300.0m | $326.3m | $378.1m | — | — | — | — | — | — | $870.5m | |
| Operating Income (Loss) | $21.1m |
$40.8m
+93.72%
|
$30.1m
-26.26%
|
($18.8m)
-162.42%
|
($6.3m)
+66.64%
|
($8.3m)
-32.70%
|
($13.3m)
-59.57%
|
($139.1m)
-948.46%
|
($84.6m)
+39.17%
|
($81.4m)
+3.77%
|
($37.3m)
+54.23%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | — | ($1.6m) | $4.4m | ($2.9m) | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | — | $1.8m | $5.1m | ($48k) | — | |
| Gain (Loss) Related to Litigation Settlement | ($14.4m) | — | — | — | — | — | — | ($14.5m) | ($15.8m) | ($33.8m) | — | |
| Other Nonoperating Income (Expense) | ($2.8m) | ($4.0m) | ($6.4m) | ($8.1m) | $8.4m | ($3.3m) | ($3.1m) | ($938k) | ($9.6m) | $8.1m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $23.0m | $27.8m | $28.6m | ($24.9m) | $5.6m | ($6.0m) | ($22.3m) | ($154.8m) | ($113.2m) | ($93.3m) | ($60.3m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $19.0m | $36.4m | $22.9m | ($27.0m) | ($368k) | ($13.5m) | ($17.7m) | ($148.7m) | ($123.9m) | ($90.8m) | ($60.3m) | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | $1.2m | $1.4m | |
| Income Tax Expense (Benefit) | $15.5m | $29.1m | $9.1m | $1.4m | ($2.9m) | $24.9m | $2.0m | $2.7m | $2.1m | $1.4m | $1.4m | |
| Net Income (Loss) Attributable to Parent | $3.1m |
$6.2m
+103.63%
|
$13.8m
+121.93%
|
($28.5m)
-306.08%
|
$2.5m
+108.84%
|
($38.4m)
-1624.79%
|
($19.7m)
+48.54%
|
($151.4m)
-666.60%
|
($126.0m)
+16.78%
|
($92.2m)
+26.83%
|
($61.7m)
+33.05%
|
|
| Earnings Per Share, Basic | $0.17 | $0.34 | $0.73 | ($1.51) | $0.13 | ($1.95) | ($0.98) | ($4.12) | ($3.30) | ($2.33) | ($1.52) | |
| Earnings Per Share, Diluted | $0.17 | $0.34 | $0.72 | ($1.51) | $0.13 | ($1.95) | ($0.98) | ($4.12) | ($3.30) | ($2.33) | ($1.52) | |
| Income (Loss) from Continuing Operations, Per Basic Share | $0 | $0 | $1 | ($2) | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | $0 | $0 | $1 | ($2) | — | — | — | — | — | — | — | |
| Weighted Average Number of Shares Outstanding, Basic | 18.1m | 18.1m | 18.5m | 18.9m | 19.3m | 19.7m | 20.1m | 36.7m | 38.1m | 39.6m | 40.3m | |
| Weighted Average Number of Shares Outstanding, Diluted | 18.5m | 18.5m | 18.9m | 18.9m | 19.4m | 19.7m | 20.1m | 36.7m | 38.1m | 39.6m | 40.3m | |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, Amortization | $6.4m | — | — | — | — | — | — | — | — | — | — | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | ($4.7m) | — | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | $11.8m | — | — | — | — | $0 | |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax | ($441k) | ($1.1m) | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $3.5m | $7.3m | $13.8m | ($28.5m) | — | — | — | — | — | — | — |